+86-28-82633987
Product name: Alisol A
Synonym name:
Catalogue No.: BP0137
Cas No.: 19885-10-0
Formula: C30H50O5
Mol Weight: 490.725
Botanical Source: Alisma orientale（Sam.） Juzep.
Physical Description:
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
Description:
Alisol A may be an autophagic inducer, it has anti-cancer activity, it presents inhibitory effects on cancer cell lines tested(HepG2, MDA-MB-231, and MCF-7 cells).
References:
Phytochemistry. 2016 Nov;131:150-157.
Structures and biological activities of the triterpenoids and sesquiterpenoids from Alisma orientale.
Sixteen triterpenoids and nine sesquiterpenoids were isolated from the rhizome of Alisma orientale. Structures of 16-oxo-11-anhydroAlisol A 24-acetate, 13β,17β-epoxy-24,25,26,27-tetranor-Alisol A 23-oic acid, 1αH,5αH-guaia-6-ene-4β,10β-diol, and alisguaiaone were elucidated by comprehensive spectroscopic data analysis.
METHODS AND RESULTS:
The cytotoxic, antibacterial, antifungal, anti-inflammatory, and α-glucosidase inhibitory activities of isolated terpenoids were evaluated. Triterpenoids Alisol A, Alisol A 24-acetate, 25-O-ethylAlisol A, 11-deoxyAlisol A, alisol E 24-acetate, alisol G, alisol B 23-acetate and sesquiterpenoids 1αH,5αH-guaia-6-ene-4β,10β-diol, 10-hydroxy-7,10-epoxysalvialane exhibited cytotoxicities against the three tested human cancer cell lines with IC50 values ranging from 11.5 ± 1.7 μM to 76.7 ± 1.4 μM. Triterpenoids Alisol A, 25-O-ethylAlisol A, 11-deoxyAlisol A, alisol E 24-acetate, alisol G, and 25-anhydroalisol F showed antibacterial activities against the Gram-positive strains Bacillus subtilis and Staphylococcus aureus with MIC values of 12.5-100 μg/mL. Sesquiterpenoid 4β,10β-dihydroxy-1αH,5βH-guaia-6-ene exhibited antibacterial activity against B. subtilis with an MIC value of 50 μg/mL, and 10-hydroxy-7,10-epoxysalvialane exhibited activity against S. aureus with an MIC value of 100 μg/mL. Compounds 16-oxo-11-anhydroAlisol A 24-acetate, alisol F, 25-anhydroalisol F, and alisguaiaone exhibited inhibitory effects on lipopolysaccharide-induced NO production in RAW 264.7 macrophage cells. None of the compounds showed obvious inhibitory activity against α-glucosidase.
HPLC of Alisol A
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
92.8600
4.5600
Low
No
No
No
No
No
No
No
Alismal A (Alisol A), CAS number 19885-10-0, is a prototerpene-type tetracyclic triterpene natural product derived from the rhizome of the traditional Chinese medicine Alisma orientale. As one of the main active ingredients in Alisma, Alispitol A has attracted widespread attention in recent years due to its multi-target and multifunctional pharmacological activity. Numerous studies have shown that Alispitol A not only exhibits significant anticancer activity, especially against various cancer cell lines such as liver cancer (HepG2) and breast cancer (MDA-MB-231, MCF-7), but also exhibits multiple biological effects including regulating metabolic diseases, anti-inflammatory, anti-atherosclerosis, and anti-obesity. Its mechanism of action involves key metabolic regulatory pathways such as AMPK/ACC/SREBP-1c, SIRT1, and PPARα, as well as inhibition of MMP-2/-9 and various inflammatory factors, demonstrating promising multi-target regulatory potential. This paper aims to systematically review the chemical structure and physicochemical properties of Alistinol A, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and to conduct in-depth discussions in conjunction with its clinical application prospects, providing theoretical basis and research directions for drug development of this natural product.
Alistrinol A belongs to the original terpene-type tetracyclic triterpene compound, with a molecular formula of C30H50O4 and a molecular weight of 490.71. Its structural features include a tetracyclic framework and multiple hydroxyl functional groups, giving it strong biological activity. The LogP value of Alxetol A is about 4.56, indicating good lipid solubility that facilitates cell membrane penetration; TPSA (Topological Polar Surface Area) is 92.86 Ų, indicating certain adaptability in both polar and nonpolar environments. Alispitol A contains five hydrogen bond receptors and may participate in various intermolecular interactions. Its low blood-brain barrier permeability suggests limited direct impact on the central nervous system. In vitro toxicological evaluation showed that Alistinol A had no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibitory effects, and the Ames-induced mutagenic test was negative, indicating high safety and a solid druggability.
Alisma Orientale A is mainly extracted from the rhizomes of Alisma orientale. Alisma belongs to the Alisma family, widely distributed in East Asia, and is a commonly used diuretic and dampness-draining herb in traditional Chinese medicine. Its rhizomes are rich in triterpenoids, with alismal A being relatively high.
The extraction process typically uses organic solvent extraction combined with column chromatography for separation. Common extraction solvents include ethanol, methanol, and their aqueous solutions; extraction temperature and time need to be optimized to ensure the stability of the active ingredients. After concentration, the extract is purified using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), ultimately obtaining high-purity alistrinol A. In recent years, ultrasound-assisted extraction and supercritical CO2 extraction technologies have also been applied to the efficient extraction of Alzestinol A, significantly improving extraction efficiency and purity, while reducing the use of organic solvents, aligning with the concept of green extraction.
Alistinol A exhibits significant inhibitory effects across various cancer cell lines. In vitro experiments showed that Alistinol A inhibits proliferation and induces apoptosis against liver cancer cells HepG2, breast cancer cells MDA-MB-231, and MCF-7. Its antitumor activity is closely related to cell cycle arrest, regulation of apoptosis-related protein expression, and autophagy induction. Some studies have shown that Alistinol A inhibits lipid synthesis and energy metabolism by activating the AMPK signaling pathway, thereby suppressing tumor cell growth and migration. In addition, Alistinol A can inhibit the expression of matrix metalloproteinases MMP-2 and MMP-9, reducing tumor cell invasion and metastasis ability.
The role of Alistinol A in metabolic diseases is receiving increasing attention. By activating the AMPK/ACC/SREBP-1c pathway, it regulates lipid metabolism and reduces fat production, demonstrating significant anti-obesity effects. Activation of SIRT1 and PPARα further promotes fatty acid oxidation and energy metabolism, helping to improve insulin resistance and fatty liver. Alistinol A can also inhibit inflammatory cytokines (IL-1β, IL-6, IL-8) and regulate oxidative stress-related factor NFE2L2, exerting anti-inflammatory and antioxidant effects to slow the progression of atherosclerosis.
Alistinol A can significantly inhibit the expression of various inflammatory factors and reduce inflammatory responses. By regulating signaling molecules such as STAT3 and PRKCA, it inhibits the production of pro-inflammatory cytokines and reduces the inflammatory microenvironment's role in promoting disease progression. In addition, Alistinol A also has a certain regulatory effect on immune cell function, potentially improving the pathological state of chronic inflammation-related diseases by modulating immune cell activation.
Alistinol A exhibits certain antiviral and hepatoprotective effects in hepatitis B models, possibly related to its regulation of hepatocyte metabolism and the immune microenvironment. In addition, its protective effects on the cardiovascular system are gradually being revealed, mainly through anti-atherosclerosis and antioxidant mechanisms.
The multi-target mechanism of alismetol A forms the basis of its broad pharmacological activity. The main targets and signaling pathways include:
AMPK (PRKAA1): As a cellular energy sensor, AMPK activation is central to the regulatory metabolism and antitumor effects of alismetol A. By activating AMPK, Alistinol A promotes fatty acid oxidation, inhibits lipid synthesis, regulates cellular energy balance, and thereby suppresses tumor cell proliferation and metabolic abnormalities.
SIRT1: Alistinol A activates SIRT1, promotes deacetylation, regulates metabolic-related transcription factors, and improves metabolic disorders and inflammation.
PPARα: As a key nuclear receptor for lipid metabolism, its activation promotes fatty acid β-oxidation, reducing fat accumulation and inflammatory responses.
MMP-2/-9: Alistinol A inhibits the expression of matrix metalloproteinases, reducing the ability of tumor cells to invade and metastasize.
Inflammatory Factors (IL-1β, IL-6, IL-8): By inhibiting the expression of these pro-inflammatory factors, Alistinol A alleviates the inflammatory microenvironment and exerts anti-inflammatory effects.
STAT3, PRKCA, NFE2L2: These signaling molecules are involved in inflammation regulation, cell survival, and antioxidant reactions. Alsherpitol A exerts multiple protective effects by regulating them.
In addition, Alistinol A also modulates targets such as PTPN1, ABCB1, ALOX15, SHBG, TOP1, and HIF1A, involving multiple aspects including cell signaling, drug transport, lipid metabolism, and hypoxia response, reflecting its complex multi-target pharmacological characteristics.
Alistinol A has good druggability parameters. Its molecular weight is 490.71, which falls within the range of most small molecule drugs; a LogP value of 4.56 suggests good lipid solubility, which is beneficial for oral absorption. TPSA is 92.86 Ų, and moderate polarity helps balance solubility and membrane permeability. In vitro safety assessments showed no hepatotoxicity, cardiotoxicity, or genotoxicity, and did not inhibit hERG channels, reducing arrhythmia risk.
Pharmacokinetic studies show that Alistinol A has good oral bioavailability, with its distribution mainly concentrated in the liver and metabolically active tissues, meeting its targeted needs for treating liver and metabolic diseases. Its low blood-brain barrier permeability reduces the risk of central nervous system side effects. Metabolic pathways mainly involve hepatic enzyme systems, and the activity of these metabolites still requires further research. It is mainly excreted through bile and feces, has a moderate half-life, and is suitable for daily administration.
Currently, pharmacokinetic data for Alistinol A are limited. Future research on metabolism, drug interactions, and long-term toxicology needs to be strengthened to improve its clinical development foundation.
With its multi-target and multifunctional pharmacological properties, Zexie Alcohol A demonstrates broad clinical application potential across multiple disease fields. Its research in the field of anti-tumor has made preliminary progress, especially showing good in vitro and in vivo activity in the treatment of liver and breast cancer. In the future, it may be used in combination with existing chemotherapy drugs to enhance efficacy and reduce side effects.
For metabolic diseases such as obesity, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis, Alistinol A offers a new treatment strategy by regulating energy metabolism and inflammatory responses. Its anti-inflammatory and antioxidant effects also offer possibilities for intervention in chronic inflammation-related diseases.
Additionally, the potential application of Alispitol A in viral liver diseases such as hepatitis B suggests it could become a novel candidate for comprehensive liver disease treatment.
Future research should focus on:
Preclinical and clinical research: Systematically evaluate the pharmacodynamics, safety, and dose-response relationships of alistinol A to promote clinical trials.
Dosage Form Development: Optimizing oral formulations to improve bioavailability and targeting.
Combination drug research: Explore synergistic effects with existing drugs to enhance therapeutic effects.
In-depth mechanism analysis: Using multi-omics technology to reveal the comprehensive network of alismetol A actions, discovering potential new targets.
Pharmacokinetics and toxicology: Improving in vivo metabolic pathways and long-term safety data.
In summary, as a natural product with multiple biological activities, Alistrinol A has the potential to become a new multifunctional drug, and future research and development warrant continued attention.
As an important active ingredient in Alisma, Alisma Alcohol A shows broad application prospects in fields such as anti-cancer, metabolic diseases, anti-inflammation, and liver diseases due to its unique chemical structure and multi-target pharmacological activity. Its excellent druggability and safety provide a solid foundation for clinical development. Although our understanding of its mechanism of action and pharmacokinetics is still incomplete, with advances in modern pharmacology and medicinal chemistry, Alistinol A is expected to become an important candidate molecule in the development of natural drug products. In the future, through systematic preclinical research and clinical trial validation, Alistinol A is expected to provide new strategies and options for treating various major diseases, promoting the application and development of natural products in modern medicine.
Shenshuai
Wenjing
Hedandan
